血清超敏C反应蛋白及尿mAlb/Cr与糖尿病视网膜病变的相关性

doi:10.3969/j.issn.1004-583X.2022.03.010

摘要/Abstract

摘要：

目的探讨血清超敏C反应蛋白(hs-CRP)、尿微量白蛋白(U-mAlb)/肌酐(Cr)与糖尿病视网膜病变(DR)的相关性及糖尿病增殖期视网膜病变(PDR)发生的危险因素。方法将150例2型糖尿病患者分为糖尿病无视网膜病变组(NDR组,67例)、糖尿病非增殖期视网膜病变组(NPDR组,55例)及PDR组(28例),分别检测3组空腹静脉血糖(FPG)、糖化血红蛋白(HbA₁c)、hs-CRP与U-mAlb/Cr并进行比较,分析hs-CRP与U-mAlb/Cr在DR不同分期中的变化以及PDR发生的危险因素。结果 hs-CRP与U-mAlb/Cr在NDR组、NPDR组及PDR组中均依次升高,PDR组高于其余2组,NPDR组高于NDR组(P<0.05); Spearman相关分析显示hs-CRP及U-mAlb/Cr与DR的严重程度呈显著正相关(P<0.05);Logistic回归分析显示hs-CRP、U-mAlb/Cr与病程均为PDR发生的危险因素(P<0.05)。结论血清hs-CRP、U-mAlb/ Cr在DR患者中呈现高表达,与其严重程度呈显著正相关,两者与病程均为PDR发生的危险因素,在DR的诊治中应重视hs-CCRP、U-mAlb/Cr的检测。

关键词: 糖尿病视网膜病变, 超敏C反应蛋白, 尿微量白蛋白, 肌酐

Abstract:

Objective To explore the correlation of serum high-sensitivity C-reactive protein (hs-CRP), urine microalbumin (U-mAlb)/ creatinine (Cr) and diabetic retinopathy (DR), and the risk factors of proliferative diabetic retinopathy (PDR). Methods Totally 150 patients with type 2 diabetes mellitus (T2DM) were divided into three groups: non DR group (NDR group, n=67), non PDR group (NPDR group, n=55) and PDR group (n=28). The subjects were detected the level of fasting venous blood glucose (FPG), glycosylated hemoglobin (HbA₁c), hs-CRP and U-mAlb/Cr; the variation of hs-CRP and U-mAlb/Cr in different stages of DR as well as the risk factors associated with PDR were analyzed. Results The levels of hs-CRP and U-mAlb/C rised gradually among the three groups, which in PDR group were most prevalent, following by NPDR group (P<0.05). Spearman correlation analysis showed that the levels of hs-CRP and U-mAlb/Cr were significantly positively correlated with the severity of DR (P<0.05). Logistic regression analysis indicated that the risk factors for PDR were hs-CRP, U-mAlb/Cr and DR disease duration (P<0.05). Conclusion The detection of hs-CRP and U-mAlb/Cr should be emphasize in the diagnosis and treatment of DR, because the high expression of which are significantly positively correlated with the severity of DR.

Key words: diabetic retinopathy, high sensitivity c-reactive protein, urine microalbumin, creatinine

中图分类号:

R587.26

王德生, 孙志刚, 马周鹏. 血清超敏C反应蛋白及尿mAlb/Cr与糖尿病视网膜病变的相关性[J]. 临床荟萃, 2022, 37(3): 253-256.

Wang Desheng, Sun Zhigang, Ma Zhoupeng. Correlation of serum high-sensitivity C-reactive protein and urine microalbumin/creatinine and retinal lesions in diabetic[J]. Clinical Focus, 2022, 37(3): 253-256.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.03.010

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I3/253

图/表 4

参考文献 19

[1]	Daniel SWT, Cheung CYL, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes[J]. JAMA, 2017, 318(22):2211-2223. doi: 10.1001/jama.2017.18152 pmid: 29234807
[2]	Xie J, Wang X Q, Zhang YY, et al. The longitudinal effect of subclinical hypothyroidism on urine microalbumin-to-urine creatinine ratio in patients with type 2 diabetes mellitus[J]. BMC Endocr Disord, 2019, 19(1):84. doi: 10.1186/s12902-019-0405-0 URL
[3]	贾伟平. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4):292-344.
[4]	Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J]. Int J Mol Sci, 2018, 19(4):942. doi: 10.3390/ijms19040942 URL
[5]	Zhao K, Liu J, Dong G, et al. Preliminary research on the effects and mechanisms of umbilical cord-derived mesenchymal stem cells in streptozotocin-induced diabetic retinopathy[J]. Int J Mol Med, 2020, 46(2):849-858. doi: 10.3892/ijmm.2020.4623 pmid: 32626946
[6]	惠延年. 精确评估和控制糖尿病视网膜病变的进展[J]. 中华眼底病杂志, 2011, 37(1):1-4.
[7]	Fehér J, Taurone S, Spoletini M, et al. Ultrastructure of neurovascular changes in human diabetic retinopathy[J]. Int J Immunopathol Pharmacol, 2018, 31:394632017748841.
[8]	Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy[J]. Front Immunol, 2020, 11:564077. doi: 10.3389/fimmu.2020.564077 URL
[9]	Mesquida M, Drawnel F, Fauser S. The role of inflammation in diabetic eye disease[J]. Semin Immunopathol, 2019, 41(4):427-445. doi: 10.1007/s00281-019-00750-7 pmid: 31175392
[10]	丁秋爱, 游志鹏. 糖尿病视网膜病变与免疫炎症关系的研究进展[J]. 南昌大学学报(医学版), 2017, 57(6):97-100.
[11]	刘晓腾, 单伟超, 侯瑞田, 等. 血清超敏C反应蛋白、脂蛋白相关性磷脂酶A2与老年原发性高血压合并2型糖尿病的相关性[J]. 临床荟萃, 2021, 36(1):25-29.
[12]	Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction[J]. Vasc Health Risk Manag, 2019, 15:221-227. doi: 10.2147/VHRM URL
[13]	Buila NB, Ntambwe ML, Mupepe DM, et al. the impact of hs-crp on cardiovascular risk stratification in pilots and air traffic controllers[J]. Aerosp Med Hum Perform, 2020, 91(11):886-891. doi: 10.3357/AMHP.5601.2020 URL
[14]	付琳, 袁霞, 钱波. 超敏C反应蛋白在不同分期糖尿病视网膜病变患者中的变化及意义[J]. 检验医学与临床, 2019, (16):2881-2883.
[15]	Tang G, Li S, Zhang C, et al. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management[J]. Acta Pharm Sin B, 2021, 11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020 URL
[16]	傅铮, 朱丽秀, 林奉森. 糖尿病视网膜病变与肾小球率过滤、尿微量白蛋白/肌酐的相关性[J]. 糖尿病新世界, 2017, 20(4):178-179, 189.
[17]	郭伟宾, 杨江萍, 侯娇娇, 等. 糖尿病视网膜病变的危险因素分析[J]. 解放军医药杂志, 2018, 30(6):46-48.
[18]	汤庆丽, 沈烨宇, 徐婉文, 等. 血糖控制达标 2 型糖尿病患者发生糖尿病视网膜病变的影响因素[J]. 国际眼科杂志, 2021, 21(11):1952-1956.
[19]	Ipp E. Diabetic retinopathy and insulin insufficiency: Beta cell replacement as a strategy to prevent blindness[J]. Front Endocrinol (Lausanne), 2021, 12:734360. doi: 10.3389/fendo.2021.734360 URL

组别	例数	性别比 (男/女)	年龄 (岁)	病程 (年)	BMI (kg/m²)
NDR组	67	2.19(46/21)	57.95±8.61	2.89±1.55	23.89±2.86
NPDR组	55	2.24(38/17)	58.12±7.59	4.72±1.37^*	24.12±2.58
PDR组	28	2.11(19/9)	58.71±6.63	6.48±2.17^*#	23.74±1.99
χ²/t值		1.05	0.97	8.66	1.33
P值		>0.05	>0.05	<0.05	>0.05

组别	例数	性别比 (男/女)	年龄 (岁)	病程 (年)	BMI (kg/m²)
NDR组	67	2.19(46/21)	57.95±8.61	2.89±1.55	23.89±2.86
NPDR组	55	2.24(38/17)	58.12±7.59	4.72±1.37^*	24.12±2.58
PDR组	28	2.11(19/9)	58.71±6.63	6.48±2.17^*#	23.74±1.99
χ²/t值		1.05	0.97	8.66	1.33
P值		>0.05	>0.05	<0.05	>0.05

组别	例数	FPG (mmol/L)	HbA₁c (%)	hs-CRP (mg/L)	U-mAlb/Cr (μg/mg)
NDR组	67	7.99±1.08	7.59±1.12	8.49±2.15	69.37±23.28
NPDR组	55	8.01±0.49	7.72±1.31	11.35±3.27^*	289.66±147.56
PDR组	28	8.03±1.14	7.86±0.79	17.07±3.49^*#	669.74±186.34
t值		1.67	1.82	19.87	79.54
P值		>0.05	>0.05	<0.05	<0.05

组别	例数	FPG (mmol/L)	HbA₁c (%)	hs-CRP (mg/L)	U-mAlb/Cr (μg/mg)
NDR组	67	7.99±1.08	7.59±1.12	8.49±2.15	69.37±23.28
NPDR组	55	8.01±0.49	7.72±1.31	11.35±3.27^*	289.66±147.56
PDR组	28	8.03±1.14	7.86±0.79	17.07±3.49^*#	669.74±186.34
t值		1.67	1.82	19.87	79.54
P值		>0.05	>0.05	<0.05	<0.05

因素	变量名	赋值说明
hs-CRP	X1	<9=1, (9~14)=2, >14=3
U-mAlb/Cr	X2	<90=1, (90~300)=2, >300=3
病程	X3	<3=1,(3~5)=2, >5=3
糖尿病增殖期视网膜眼病	Y	无=0,有=1